生物制剂DMARDs治疗银屑病关节炎真实世界有效性与应答特征:模拟多中心临床试验
该研究在模拟多中心临床试验框架下,前瞻性纳入990例中高疾病活动度银屑病关节炎患者,比较TNF抑制剂、IL-17抑制剂和IL-23通路抑制剂的6个月有效性与长期药物留存。三类bDMARDs的DAPSA改善轨迹无显著统计学差异,6个月后长期留存亦无显著差异;部分不同应答模式可能支持个体化选择。
要点
- 三类bDMARDs治疗6个月DAPSA均显著下降,校正后组间轨迹无统计学显著差异。
- 6个月时仍在用药者的后续长期药物留存,组间无统计学显著差异。
- 较短病程在部分探索性分析中与更有利结局相关,但需视为假设生成。
核心结论
- 在模拟多中心临床试验的真实世界数据中,bDMARDs治疗银屑病关节炎的短期有效性总体轨迹和长期治疗持续性相当。
- 识别出的部分不同应答模式可能支持更个体化的bDMARD选择。
研究设计与样本
- 研究为前瞻性多中心Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale研究,采用模拟目标临床试验框架分析真实世界数据。
- 2022年1月至2025年6月连续纳入中高疾病活动度、开始bDMARD治疗的银屑病关节炎患者,共990例。
- 比较TNF抑制剂(342例)、IL-17抑制剂(313例)和IL-23通路抑制剂(335例),采用倾向评分加权提高基线可比性。
主要发现
- 全部3个治疗组DAPSA在6个月内均显著下降,校正后纵向轨迹组间无统计学显著差异。
- 在6个月时仍使用索引bDMARD的患者中,校正分析未发现后续长期药物留存存在统计学显著组间差异。
- 部分探索性分析中较短病程与更有利结局相关,而既往bDMARD暴露的关联不一致。
- 常规临床记录中记录了不良事件相关停药,但研究设计不支持正式的安全性比较结论。
关键数值与推荐
- 有效性主要指标为6个月内银屑病关节炎疾病活动指数(DAPSA)的纵向变化。
- 长期药物留存采用6个月界标分析,仅限第6个月时仍使用索引bDMARD的患者。
临床怎么用
- 真实世界实践中三类bDMARDs在银屑病关节炎的短期有效性和长期持续性总体相当,选择时可综合个体化因素。
- 较短病程在部分探索性分析中与更有利结局相关,但需进一步验证后用于临床决策。
局限性
- 研究为观察性真实世界数据模拟试验,尽管采用倾向评分加权,仍不能排除未测量混杂。
- 不良事件相关停药仅来自常规临床记录描述,研究未设计用于正式比较安全性。
- 部分类特异性关联及既往bDMARD暴露的关联为探索性、假设生成性质,结果不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate 6-month effectiveness and long-term drug-retention rates of biologic disease-modifying antirheumatic drugs (bDMARDs) in psoriatic arthritis (PsA) using real-world data analysed within an emulated multicentre clinical trial framework. Secondary objectives included the characterisation of response profiles and the identification of possible predictors of clinical response across bDMARD classes. METHODS: Between January 2022 and June 2025, consecutive patients with moderate-to-high PsA disease activity initiating a bDMARD were prospectively enrolled in a multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale study. Real-world data were analysed within a target trial emulation framework comparing tumour necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-23-pathway inhibitors. Propensity score weighting was used to improve comparability in measured baseline characteristics across treatment groups. Effectiveness was assessed through longitudinal changes in the Disease Activity Index for Psoriatic Arthritis (DAPSA) over 6 months. Subsequent long-term drug retention was evaluated using a 6-month landmark analysis restricted to patients who remained on the index bDMARD at month 6. Potential clinical factors associated with treatment response and discontinuation were also explored. RESULTS: Overall, 990 patients were included: 342 initiated TNF inhibitors, 313 IL-17 inhibitors, and 335 IL-23-pathway inhibitors. DAPSA decreased significantly over 6 months in all 3 treatment groups, with no statistically significant between-class differences in adjusted longitudinal trajectories. Among patients who remained on the index bDMARD through month 6, the adjusted analyses did not identify statistically significant between-class differences in subsequent long-term drug retention. Shorter disease duration was associated with more favourable outcomes in selected exploratory analyses, whereas associations with previous bDMARD exposure were inconsistent. Additional class-specific associations were identified but should be considered exploratory and hypothesis-generating. Adverse-event-related discontinuations documented in routine clinical records were described; however, the study was not designed to support formal comparative safety conclusions. CONCLUSIONS: In this real-world emulated multicentre clinical trial, bDMARDs showed comparable overall trajectories of short-term effectiveness and long-term treatment persistence in PsA. The identification of partially distinct response patterns may support a more individualised approach to bDMARD selection.
引用
- Ruscitti P, Masedu F, Pantano I, et al. Real‑world assessment of the effectiveness and response profiles of biologic DMARDs in psoriatic arthritis: findings from an emulated multicentre clinical trial. Ann Rheum Dis. 2026. PMID: 42951730. doi:10.1016/j.ard.2026.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。